FDMT

4D Molecular Therapeutics, Inc.

22.42 USD
-0.19 (-0.84%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

4D Molecular Therapeutics, Inc. stock is down -14.23% since 30 days ago. The next earnings date is Aug 7, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 3 June’s closed higher than May. In the last 5 Unusual Options Trades, there were 2 CALLs, 3 PUTs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
24 Apr 15:27 21 Jun, 2024 25.00 CALL 91 10
29 Apr 16:43 19 Jul, 2024 2.50 CALL 40 80
17 Jun 18:32 19 Jul, 2024 22.50 PUT 153 33
18 Jun 19:10 19 Jul, 2024 20.00 PUT 500 13
20 Jun 19:58 19 Jul, 2024 20.00 PUT 169 514

About 4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa, choroideremia, and 4 D-310.